Abstracts tagged "IL-6R signaling"

Abstract Number: 2753 • 2015 ACR/ARHP Annual Meeting
Effectiveness and Safety of Tocilizumab in Biologics-Naive RA Patients – Postmarketing Surveillance for Investigating Success in Achieving Clinical and Functional Remission and Sustaining Efficacy with Tocilizumab in Biologics-Naive RA Patients (FIRST Bio) Study
Naoki Ishiguro¹, Tatsuya Atsumi², Masayoshi Harigai³, Tsuneyo Mimori⁴, Norihiro Nishimoto⁵, Takayuki Sumida⁶, Tsutomu Takeuchi⁷, Yoshiya Tanaka⁸, Nobuhiro Takagi⁹, Ayako Nakasone¹⁰ and Hisashi Yamanaka¹¹, ¹Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³Department of Phamacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Dept of Rheum & Clinical Immun, Kyoto Univ Grad Schl of Med, Kyoto, Japan, ⁵Osaka Rheumatology Clinic, Osaka, Japan, ⁶Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁷Keio University School of Medicine, Tokyo, Japan, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Medical Science, Chugai Pharmaceutical, Tokyo, Japan, ¹⁰Chugai Pharmaceutical Co. Ltd, Tokyo, Japan, ¹¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: The all-patient postmarketing surveillance (PMS) of tocilizumab (TCZ; PMS7901), which followed 7901 rheumatoid arthritis (RA) patients for 28 weeks (wks), showed that patients with…
Abstract Number: 2877 • 2014 ACR/ARHP Annual Meeting
Novel Function of Tocilizumab As a Modulator of Interleukin-27-Mediated Anti-Inflammatory Responses
Misato Hashizume¹, Jun Kikuchi², Keiko Yoshimoto² and Tsutomu Takeuchi², ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose The immunological roles of interleukin 27 (IL-27) have been reported in the function of regulatory T cells (Treg), monocytes and osteoclasts, and these cells…
Abstract Number: 2803 • 2014 ACR/ARHP Annual Meeting
Methotrexate Impacts the Effects of Tofacitinib, but Not Tocilizumab, on Clinically Relevant Biomarkers in Human Primary Cell–Based BioMAP^® Disease Models: Can We Utilize in Vitro Models to Predict Clinical Outcomes?
Alison O'Mahony¹, Ellen L. Berg¹, Xitong Li¹, Markus R. John², Kandeepan Ganeshalingam² and Ernest H. Choy³, ¹BioSeek, South San Francisco, CA, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Cardiff University, Cardiff, United Kingdom
Background/Purpose: A number of trials have shown that adding MTX benefits some, but not all, biologics and small molecules to treat RA. Specifically, though treatment…
Abstract Number: 2363 • 2014 ACR/ARHP Annual Meeting
Leucine-Rich Alpha-2 Glycoprotein Is a Potential Disease Activity Marker Under IL-6 Suppression in Autoimmune Arthritis
Yusuke Takahashi¹, Minoru Fujimoto², Satoshi Serada³ and Tetsuji Naka², ¹a doctoral student, Osaka university, Suita city, Japan, ²Laboratory for immune signal, National Institute of Biomedical Innovation, Ibaraki, Japan, ³7-6-8, Saito-asagi, National Institute of Biomedical Innovation, Laboratory for immune signal, Japan, Ibaraki, Japan
Background/Purpose C-reactive protein (CRP) is frequently used to evaluate inflammation in patients with rheumatoid arthritis (RA). However, CRP is normalized when IL-6 function is potently…
Abstract Number: 1621 • 2014 ACR/ARHP Annual Meeting
A Shift Towards Trans-Signalling Explains Relatively Low CRP Despite an Active Interleukin-6 (IL-6)/IL-6-Receptor (IL-6R) System in SLE
Martyna Skwarek, Babett Heschel, Julia Fantana and Martin Aringer, Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany
Background/Purpose IL-6 has been found increased in SLE, while CRP, which is directly stimulated by IL-6, usually remains low. We therefore analyzed the IL-6/ IL-6…
Abstract Number: 1498 • 2014 ACR/ARHP Annual Meeting
ALX-0061, an Anti-IL-6R Nanobody^®foruse in Rheumatoid Arthritis, Demonstrates a Different in Vitro Profile As Compared to Tocilizumab
Maarten Van Roy¹, Ariella Van De Sompel², Kristi De Smet², Jasper Jacobs², Tinneke Denayer² and Hans Ulrichts³, ¹Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ²Ablynx N.V., Zwijnaarde, Belgium, ³Pharmacology, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor, which can either be soluble (sIL-6R) or membrane-bound…
Abstract Number: 1479 • 2014 ACR/ARHP Annual Meeting
Impact of Clinical Remission on Physical Function in Patients with Rheumatoid Arthritis Treated with ALX-0061: Post-Hoc Analysis of Phase I/II Data
Katrien Van Beneden¹, Katrien Verschueren¹, Wouter Willems¹, Heidi Wouters¹, Joke D'Artois¹, Katelijne De Swert¹, Steven De Bruyn¹ and Gerhard Arold², ¹Clinical Development, Ablynx nv, Zwijnaarde, Belgium, ²Medical Affairs, PRA International GmbH, Berlin, Germany
Background/Purpose: ALX-0061 is a monovalent IL-6R targeting Nanobody, inhibiting signaling via soluble and membrane IL-6R. The safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of ALX-0061 was…
Abstract Number: 814 • 2014 ACR/ARHP Annual Meeting
Tocilizumab in Giant Cell Arteritis: Multicenter Open-Label Study of 22 Patients
Montserrat Santos-Gómez¹, Javier Loricera¹, Ricardo Blanco¹, Jose L. Hernández², Antonio Mera³, Eva Pérez-Pampin⁴, M. Enriqueta Peiró¹, Santos Castañeda-Sanz⁵, Alicia Humbría⁶, Jaime Calvo-Alen⁷, Elena Aurrecoechea⁸, Javier Narváez⁹, Amalia Sánchez-Andrade¹⁰, Paloma Vela¹¹, Elvira Díez Álvarez¹², Cristina Mata¹³, Pablo Lluch Mesquida¹⁴, Concepcion Moll Tuduri¹⁴, Vanesa Calvo-Río¹, Francisco Ortiz-Sanjuán¹, Trinitario Pina Murcia¹⁵, Carmen Gonzalez-Vela¹⁶, Leyre Riancho-Zarrabeitia¹ and Miguel A. González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Hospital Clínico Universitario de Santiago de Compostela. Spain, Santiago de Compostela, Spain, ⁴Rheumatology, Hospital Clínico Universitario de Santiago de Compostela. Spain, Santiago de Compostela, Spain, ⁵Rheumatology, Hospital Universitario de La Princesa. Madrid. Spain, Madrid, Spain, ⁶Rheumatology, Hospital Universitario de La Princesa. IIS-Princesa, Madrid, Madrid, Spain, ⁷Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁸Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁹Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ¹⁰Rheumatology, Hospital Universitario Lucus Augusti. Lugo. Spain, Lugo, Spain, ¹¹Rheumatology, Hospital General de Alicante. Spain, Alicante, Spain, ¹²Rheumatology, Hospital de León. Spain, León, Spain, ¹³Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ¹⁴Hospital Mateu Orfila. Menorca. Spain, Mahón (Menorca), Spain, ¹⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ¹⁶Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose Giant cell arteritis (GCA) is a primary vasculitis that involves the aorta and its major branches. It usually affects people aged more than 50…
Abstract Number: 80 • 2014 ACR/ARHP Annual Meeting
Cellular Responses of IL6 Inhibition (Tocilizumab) in Rheumatoid Arthritis Using High-Accuracy Tandem Mass Spectrometry
Michael Kruse Meyer¹, Marlene Andersen², Grethe N. Andersen¹ and Allan Stensballe³, ¹Clinic of Rheumatology, Hospital of Vendsyssel/Aalborg University, Hjørring, Denmark, ²Department of Rheumatology, Aalborg University, Hjørring, Denmark, ³Health Science and Technology, Aalborg University, Aalborg, Denmark
Background/Purpose: In this study we are analyzing leukocyte subtype responses from patients with rheumatoid arthritis (RA) to IL6 inhibition. A large contribution to RA immunopathogenesis…
Abstract Number: 30 • 2014 ACR/ARHP Annual Meeting
Inhibiting Autocrine Interleukin-6 (IL-6) Trans-Signalling in Human CD14^+VE Monocultures Reduces Osteoclast Differentiation
Lauren A. Jordan¹, Fraser L. Collins², Simon A. Jones¹, Ernest H. Choy³, Ann K. Harvey¹ and Anwen S. Williams¹, ¹Cardiff University, Institute of Infection and Immunity, School of Medicine, Cardiff, United Kingdom, ²Michigan State University, Department of Physiology, East Lansing, MI, ³Section of Rheumatology, Cardiff University, Institute of Infection and Immunity, School of Medicine, Cardiff, United Kingdom
Background/Purpose: Interleukin-6 (IL-6) and the inflammatory CC-chemokine CCL3 are highly expressed in rheumatoid arthritis, juvenile idiopathic arthritis and multiple myeloma. While these mediators contribute to…
Abstract Number: 2399 • 2013 ACR/ARHP Annual Meeting
Altered Histone Methylation Is Associated With IL-6 Dependent Matrix Metalloproteinases Gene Transcriptional Activation In Rheumatoid Arthritis Synovial Fibroblasts
Yasuto Araki^1,2, Takuma Tsuzuki Wada^1,2, Kojiro Sato¹, Kazuhiro Yokota¹, Fumihiko Miyoshi¹, Yu F. Asanuma³, Yuji Akiyama¹ and Toshihide Mimura^1,2, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Project Research Division, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan, ³Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease which causes progressive joint destruction. In spite of the modern medications including biologic reagents, it…
Abstract Number: 1866 • 2013 ACR/ARHP Annual Meeting
Primary Human Cell BioMAP^® Profiling Of Methotrexate, Tocilizumab, Adalimumab, and Tofacitinib Reveals Different Mechanisms Of Action With Distinct Phenotypic Signatures
Seng-Lai Tan¹, Alison O'Mahony², Ellen L. Berg², Kandeepan Ganeshalingam³ and Ernest H. Choy⁴, ¹Inflammation, Hoffmann-La Roche, Nutley, NJ, ²BioSeek, South San Francisco, CA, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Proinflammatory cytokines cause joint inflammation and destruction in patients with rheumatoid arthritis, as exemplified by the therapeutic success of inhibiting tumor necrosis factor alpha…
Abstract Number: 667 • 2013 ACR/ARHP Annual Meeting
IL6 and CCL2 Co-Regulate Fibroblast Dependent Trans-Endothelial Migration Of Mononuclear Cells and Fibrotic Response In Scleroderma
Rebecca Alade¹, Korsa Khan², Xu Shiwen³, Christopher P. Denton⁴ and Voon Ong⁵, ¹Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School, London, United Kingdom, ²Centre for Rheumatology and Connective Tissue Diseases, UCL medical School, London, United Kingdom, ³Rheumatology, Royal Free Hospital, London, United Kingdom, ⁴Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ⁵Department of Rheumatology, UCL Medical School, London, England
Background/Purpose: IL6 is a key mediator recently implicated in activation of extracellular matrix (ECM) proteins in scleroderma (SSc) fibroblasts. CCL2 is a proinflammatory chemokine that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].